Literature DB >> 23161117

Efficacy and toxicity of (chemo)radiotherapy for primary subglottic cancer.

M Hata1, T Taguchi, I Koike, G Nishimura, M Takahashi, M Komatsu, D Sano, K Odagiri, Y Minagawa, T Inoue.   

Abstract

BACKGROUND AND
PURPOSE: Primary subglottic cancer is a rare malignancy. We investigated the efficacy and toxicity of radiotherapy for subglottic cancer. PATIENTS AND METHODS: Nineteen patients with primary squamous cell carcinoma of the subglottis received radiotherapy, 14 of whom also underwent chemotherapy. Of the 19 patients, 15 received definitive radiotherapy to the gross tumors with total doses of 70-70.2 Gy in 35-39 fractions, and 4 underwent preoperative radiotherapy with total doses of 37.8-55.8 Gy in 21-31 fractions, followed by total laryngectomy.
RESULTS: Of the 19 patients, 5 developed local progression and 2 developed distant metastasis at the median follow-up period of 5 years. The 5-year local control and disease-free rates were 74 and 63%, respectively. Three patients died of tumor progression, and the 5-year overall and disease-free survival rates were 80 and 63%, respectively. Regarding acute toxicities, transient mucositis and dermatitis of grade 3 or lower were observed in all patients, but there were no late toxicities of grade 3 or higher.
CONCLUSION: Radiotherapy is a safe and effective treatment for patients with primary squamous cell carcinoma of the subglottis. The use of chemotherapy together with radiotherapy may enhance treatment efficacy and contribute to larynx preservation through good local control.

Entities:  

Mesh:

Year:  2012        PMID: 23161117     DOI: 10.1007/s00066-012-0178-0

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  31 in total

Review 1.  The pathology and management of subglottic cancer.

Authors:  A Ferlito; A Rinaldo
Journal:  Eur Arch Otorhinolaryngol       Date:  2000       Impact factor: 2.503

2.  THE NORMAL HUMAN LARYNGEAL LYMPHATICS.

Authors:  L W WELSH
Journal:  Ann Otol Rhinol Laryngol       Date:  1964-09       Impact factor: 1.547

3.  Clinical and surgical problems of cancer of the larynx and hypopharynx; a review 570 consecutive cases operated on in the Ear, Nose and Throat Clinic of the University of Milan between 1948 and 1954, with special regard to the problem of metastases.

Authors:  L PIETRANTONI; R FIOR
Journal:  Acta Otolaryngol Suppl       Date:  1958

4.  Squamous cell carcinoma of the subglottis.

Authors:  Jimmy Garas; W Fred McGuirt
Journal:  Am J Otolaryngol       Date:  2006 Jan-Feb       Impact factor: 1.808

5.  Definitive radiochemotherapy of advanced head and neck cancer with carboplatin and paclitaxel : a phase II study.

Authors:  Robert Semrau; Susanne Temming; Simon Florian Preuss; Jens Peter Klubmann; Orlando Guntinas-Lichius; Rolf-Peter Müller
Journal:  Strahlenther Onkol       Date:  2011-09-23       Impact factor: 3.621

6.  Comparison of radiochemotherapy alone to surgery plus radio(chemo)therapy for non-metastatic stage III/IV squamous cell carcinoma of the head and neck: A matched-pair analysis.

Authors:  Dirk Rades; Thekla Meyners; Nadja Kazic; Amira Bajrovic; Volker Rudat; Steven E Schild
Journal:  Strahlenther Onkol       Date:  2011-08-16       Impact factor: 3.621

7.  Concurrent chemoradiotherapy with cisplatin, 5-fluorouracil, methotrexate, and leucovorin in patients with advanced resectable squamous cell carcinoma of the larynx and hypopharynx.

Authors:  Takahide Taguchi; Mamoru Tsukuda; Yasukazu Mikami; Hideki Matsuda; Choichi Horiuchi; Takafumi Yoshida; Goshi Nishimura; Jun-Ichi Ishitoya; Hideaki Katori
Journal:  Acta Otolaryngol       Date:  2006-04       Impact factor: 1.494

8.  Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients.

Authors:  Jean-Pierre Pignon; Aurélie le Maître; Emilie Maillard; Jean Bourhis
Journal:  Radiother Oncol       Date:  2009-05-14       Impact factor: 6.280

9.  Concurrent chemoradiotherapy for T4 patients with hypopharyngeal and laryngeal squamous cell carcinomas.

Authors:  Goshi Nishimura; Mamoru Tsukuda; Choichi Horiuchi; Kenichi Satake; Takafumi Yoshida; Junichi Nagao; Mariko Kawakami; Norio Kondo; Yasuhiro Arai; Takahide Taguchi; Hideki Matsuda; Yasukazu Mikami
Journal:  Auris Nasus Larynx       Date:  2007-06-28       Impact factor: 1.863

10.  Efficacy of concurrent chemoradiotherapy for T1 and T2 laryngeal squamous cell carcinoma regarding organ preservation.

Authors:  Goshi Nishimura; Mamoru Tsukuda; Yasukazu Mikami; Hideki Matsuda; Choichi Horiuchi; Takahide Taguchi; Masahiro Takahashi; Mariko Kawakami; Makiko Watanabe; Tatsuo Niho; Hiroaki Abo; Sayaka Yamomoto
Journal:  Anticancer Res       Date:  2009-02       Impact factor: 2.480

View more
  3 in total

1.  Survival of patients with subglottic squamous cell carcinoma.

Authors:  S D MacNeil; K Patel; K Liu; S Shariff; J Yoo; A Nichols; K Fung; A X Garg
Journal:  Curr Oncol       Date:  2018-12-01       Impact factor: 3.677

2.  Squamous cell carcinoma of the larynx with subglottic extension: is larynx preservation possible?

Authors:  A Levy; P Blanchard; S Temam; M-M Maison; F Janot; H Mirghani; F Bidault; J Guigay; A Lusinchi; J Bourhis; N Daly-Schveitzer; Y Tao
Journal:  Strahlenther Onkol       Date:  2014-03-04       Impact factor: 3.621

3.  Apatinib combined with concurrent chemoradiotherapy in patients with subglottic small cell carcinoma: a case report.

Authors:  Man Chen; Shuang Wu; Zelai He; Zenong Cheng; Shimiao Duan; Hao Jiang; Gengming Wang
Journal:  J Int Med Res       Date:  2021-05       Impact factor: 1.671

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.